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Medullary thyroid carcinoma (MTC) is an epithelial tumor
of the thyroid gland, derived from thyroid parafollicular
C cells and represents approximately 4% of thyroid carci-
nomas. In 50 % of patients, MTC is diagnosed at an
advanced stage. Due to a lack of TSH receptors on C-cells
surface MTC does not respond to suppression therapy
with TSH and radio-iodine treatment, and thereby it con-
ferring worse outcomes overall. 5-year survival rates range
from 75% for patients with stage III disease to 40% for
patients with stage IV disease.
MTC is associated with one of three clinically different,
inherited endocrine syndromes caused by germline muta-
tions in the RET gene. It encodes a transmembrane recep-
tor tyrosine kinase which is expressed in cells derived
from the neural crest.
Activating mutations in the RET gene are detected in
the majority (95%) patients with an inherited medullary
thyroid carcinoma and approximately 30-50% of cases
without family history.
Familial medullary thyroid carcinomas (FMTCs) are
associated with mutations in codons 609, 611, 618, and
620 (exon 10), as well as codon 768 (exon 13) and codon
804 (exon 14). In FMTC patients, MTC is often the only
clinical symptom. Multiple endocrine neoplasia (MEN) 2A
is associated in the most cases, with RET gene mutations
in codons 609, 611, 618, and 620, as well as in codon 634.
Patients with MEN2A typically have MTC, pheochromo-
cytoma, and primary hyperparathyroidism (PHPT).
Patients diagnosed with MEN 2B present the most aggres-
sive type of MTC, pheochromocytoma but not PHPT,
musculoskeletal abnormalities and other developmental
defects. This syndrome is associated mostly with mutation
in codon 918 in exon 16.
Here we report the RET gene mutations spectrum in a
group from Great Poland (Wielkopolska) region. Molecu-
lar analysis was performed for 304 individuals: patients
with diagnosed MTC or apparent MEN 2A syndrome and
first and second degree relatives. Studied group included
also one family with MEN 2B syndrome. All patients were
diagnosed in the Department of Endocrinology, Metabo-
lism, and Internal Diseases of the Poznan University of
Medical Sciences. We screened RET gene exons: 10, 11,
13-16 using pyrosequencing for specific codons and
HRMA technique followed by Sanger sequencing.
Identification of RET gene mutations was possible for 50
patients (32%). This group included 12 family cases and in
6 subjected individuals diagnosis were possible before can-
cer occurring. In a group of 106 (68%) MTC patients we
did not detect mutations in analyzed RET gene regions.
The most frequent was missense substitutions occurring
in codon 634 (72%): C634R (58%), C634G (10%) and
C634Y (4%). Surprisingly, in our group of patients we did
not detect mutations in exon 10, as they are frequent in
other populations. However, we observed 3 different
mutations in exon 13 (18%) and in exon 14 (6%). In four
unrelated patients with negative family history we detected
missense change Y791F, which is associated with late
onset MTC, but interestingly one of patients was homozy-
gous and presented more aggressive course of the disease
(characterized with multifocality and onset in the moment
of diagnosis at 47 years of age). In MEN 2B family,
M918A mutation was detected.
Due to the fact, that we observe a different mutational
spectrum in our patients, we consider more extensive ana-
lysis of the RET gene as reasonable.
1Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland
Full list of author information is available at the end of the article
Kaczmarek-Ryś et al. Hereditary Cancer in Clinical Practice 2015, 13(Suppl 2):A12
http://www.hccpjournal.com/content/13/S2/A12
© 2015 Kaczmarek-Ryś et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ details
1Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
2The Department of Endocrinology, Metabolism and Internal Diseases,
University of Medical Sciences, Poznan, Poland. 3The NanoBioMedical Center,
Adam Mickiewicz University, Poznan, Poland.
Published: 26 November 2015
doi:10.1186/1897-4287-13-S2-A12
Cite this article as: Kaczmarek-Ryś et al.: RET gene mutations spectrum
in patients with medullary thyroid carcinoma (MTC) from Great Poland
region. Hereditary Cancer in Clinical Practice 2015 13(Suppl 2):A12.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kaczmarek-Ryś et al. Hereditary Cancer in Clinical Practice 2015, 13(Suppl 2):A12
http://www.hccpjournal.com/content/13/S2/A12
Page 2 of 2
